Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

West Pharmaceutical Services (WPS) Stock Price & Analysis

WPS Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 23.71B
Enterprise Value
CHF 26.10B
Total Cash (Recent Filing)
CHF 464.10M
Total Debt (Recent Filing)
CHF 305.00M
Price to Earnings (P/E)
46.0
Beta
0.99
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
1.88
Next Dividend Ex-Date
N/A
Dividend Yield
0.21%

Bulls Say, Bears Say

Bulls Say

High-Value Product Leadership

High-value components are central to West’s revenue base and benefit from biologics, GLP-1 therapies, and qualified customer applications. Their critical role in injectable containment can support repeat demand, stronger product mix, and durable competitive positioning over the next several quarters.

Raised Growth And Margin Outlook

Management’s higher revenue outlook and planned margin expansion indicate strong underlying demand and operating execution rather than reliance solely on temporary volume. Improved mix, pricing, plant performance, and leverage can strengthen earnings power and support reinvestment in growth.

Conservative Balance Sheet And Cash Generation

Low leverage gives West meaningful financial flexibility across industry cycles and reduces pressure from interest obligations. Healthy operating and free cash flow provide internal funding for capacity expansion, customer support, dividends, and other strategic priorities without depending heavily on additional debt.

Bears Say

West Vantage Portfolio Transition

The West Vantage decline shows that portfolio transition is currently offsetting gains from new, higher-value drug-handling programs. Muted growth expected this year and next could weigh on consolidated momentum while replacement projects ramp and legacy revenue continues to roll off.

Uneven Cash Conversion

Working-capital investment is absorbing more cash even as operations expand, reducing near-term cash conversion and limiting the portion of earnings available for discretionary uses. If receivables and inventory remain elevated, funding capacity for buybacks, dividends, or expansion could be less efficient.

Delivery Device And SmartDose Headwinds

The delivery-device business has uneven quarterly performance, and the SmartDose 3.5 divestiture removes an existing revenue stream. These factors can make reported growth less consistent and require new product adoption and customer programs to offset the resulting portfolio headwind.

West Pharmaceutical Services News

WPS FAQ

What is West Pharmaceutical Services’s market cap?
West Pharmaceutical Services’s market cap is CHF23.71B.
When is West Pharmaceutical Services’s upcoming earnings report date?
West Pharmaceutical Services’s next earnings report is estimated for Feb 18, 2027 (not yet confirmed), which is in 108 days.
How were West Pharmaceutical Services’s earnings last quarter?
West Pharmaceutical Services released its earnings results on Oct 29, 2026. The company reported CHF2.191 earnings per share for the quarter, beating the consensus estimate of CHF1.813 by CHF0.378.
Is West Pharmaceutical Services overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does West Pharmaceutical Services pay dividends?
West Pharmaceutical Services does not currently pay dividends.
What is West Pharmaceutical Services’s EPS estimate?
West Pharmaceutical Services’s EPS estimate is 1.88.
How many shares outstanding does West Pharmaceutical Services have?
West Pharmaceutical Services has 69,661,030 shares outstanding.
What happened to West Pharmaceutical Services’s price movement after its last earnings report?
West Pharmaceutical Services reported an EPS of CHF2.191 in its last earnings report, beating expectations of CHF1.813. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of West Pharmaceutical Services?
Hedge funds hold West Pharmaceutical Services shares: the largest hedge-fund position in West Pharmaceutical Services is 263,087,824 shares, and hedge funds decreased their holdings by 863.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology